Cargando…

Protocol for the EARCO Registry: a pan-European observational study in patients with α(1)-antitrypsin deficiency

RATIONALE AND OBJECTIVES: Alpha-1 antitrypsin deficiency (AATD) is a genetic condition that leads to an increased risk of emphysema and liver disease. Despite extensive investigation, there remain unanswered questions concerning the natural history, pathophysiology, genetics and the prognosis of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greulich, Timm, Altraja, Alan, Barrecheguren, Miriam, Bals, Robert, Chlumsky, Jan, Chorostowska-Wynimko, Joanna, Clarenbach, Christian, Corda, Luciano, Corsico, Angelo Guido, Ferrarotti, Ilaria, Esquinas, Cristina, Gouder, Caroline, Hećimović, Ana, Ilic, Aleksandra, Ivanov, Yavor, Janciauskiene, Sabina, Janssens, Wim, Kohler, Malcolm, Krams, Alvils, Lara, Beatriz, Mahadeva, Ravi, McElvaney, Gerry, Mornex, Jean-François, O'Hara, Karen, Parr, David, Piitulainen, Eava, Schmid-Scherzer, Karin, Seersholm, Niels, Stockley, Robert A., Stolk, Jan, Sucena, Maria, Tanash, Hanan, Turner, Alice, Ulmeanu, Ruxandra, Wilkens, Marion, Yorgancioğlu, Arzu, Zaharie, Ana, Miravitlles, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2020
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049712/ https://www.ncbi.nlm.nih.gov/pubmed/32154291 http://dx.doi.org/10.1183/23120541.00181-2019

Ejemplares similares

Research priorities in α(1)-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration
por: Barrecheguren, Miriam, et al.
Publicado: (2020)

Impact of COVID-19 in Patients With Severe Alpha-1 Antitrypsin Deficiency: The IMCA1 Study of the EARCO Clinical Research Collaboration
por: Parr, David G., et al.
Publicado: (2022)

Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
por: Miravitlles, Marc, et al.
Publicado: (2022)

Correction: Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
por: Miravitlles, Marc, et al.
Publicado: (2023)

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018)

New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency
por: Chorostowska-Wynimko, Joanna, et al.
Publicado: (2020)

Diagnosis and management of α(1)-antitrypsin deficiency in Europe: an expert survey
por: Horváth, Ildikó, et al.
Publicado: (2019)

Opinions and Attitudes of Pulmonologists About Augmentation Therapy in Patients with Alpha-1 Antitrypsin Deficiency. A Survey of the EARCO Group
por: Greulich, Timm, et al.
Publicado: (2022)

Post-Translational Modifications of Circulating Alpha-1-Antitrypsin Protein
por: Lechowicz, Urszula, et al.
Publicado: (2020)

Demographic and clinical characteristics of patients with α(1)-antitrypsin deficiency genotypes PI*ZZ and PI*SZ in the Spanish registry of EARCO
por: Torres-Durán, María, et al.
Publicado: (2022)

Inhaled therapies in patients with moderate COPD in clinical practice: current thinking
por: Ariel, Amnon, et al.
Publicado: (2017)

The prevalence of bronchiectasis in patients with alpha-1 antitrypsin deficiency: initial report of EARCO
por: Stockley, Robert A., et al.
Publicado: (2023)

The Multifaceted Effects of Alpha1-Antitrypsin on Neutrophil Functions
por: Janciauskiene, Sabina, et al.
Publicado: (2018)

Targeted screening programmes in COPD: how to identify individuals with α(1)-antitrypsin deficiency
por: Chorostowska-Wynimko, Joanna
Publicado: (2015)

PAI-1 Level Differences in Malignant Plural Effusion, Parapneumonic Pleuritis, and Cardiac Hydrothorax
por: Zentina, Dace, et al.
Publicado: (2019)

Does urinary peptide content differ between COPD patients with and without inherited alpha-1 antitrypsin deficiency?
por: Carleo, Alfonso, et al.
Publicado: (2017)

How Can We Improve the Detection of Alpha1-Antitrypsin Deficiency?
por: Ferrarotti, Ilaria, et al.
Publicado: (2015)

Quantitative disease progression model of α‐1 proteinase inhibitor therapy on computed tomography lung density in patients with α‐1 antitrypsin deficiency
por: Tortorici, Michael A., et al.
Publicado: (2017)

Liver disease in adults with severe alpha-1-antitrypsin deficiency
por: Tanash, Hanan A., et al.
Publicado: (2019)

Fibroblast Growth Factor Receptor 1-4 Genetic Aberrations as Clinically Relevant Biomarkers in Squamous Cell Lung Cancer
por: Moes-Sosnowska, Joanna, et al.
Publicado: (2022)

SERPINA1 and More? A Putative Genetic Contributor to Pulmonary Dysfunction in Alpha-1 Antitrypsin Deficiency
por: Jezela-Stanek, Aleksandra, et al.
Publicado: (2023)

Clinical considerations in individuals with α(1)-antitrypsin PI*SZ genotype
por: McElvaney, Gerard N., et al.
Publicado: (2020)

The importance of effective registries in pulmonary diseases and how to optimize their output
por: Chorostowska-Wynimko, Joanna, et al.
Publicado: (2019)

Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study
por: Schneider, Marc A., et al.
Publicado: (2022)

Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37–40 years
por: Piitulainen, Eeva, et al.
Publicado: (2017)

Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43–45 years
por: Mostafavi, Behrouz, et al.
Publicado: (2019)

The Clinical Course of Severe Alpha-1-Antitrypsin Deficiency in Patients Identified by Screening
por: Hiller, Adriana-Maria, et al.
Publicado: (2022)

Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme
por: Greulich, Timm, et al.
Publicado: (2018)

Diagnosing α(1)-antitrypsin deficiency: how to improve the current algorithm
por: McElvaney, Noel G.
Publicado: (2015)

Interleukin-6: obstacles to targeting a complex cytokine in critical illness
por: McElvaney, Oliver J, et al.
Publicado: (2021)

Reply to Blot et al. and to Inoue et al.
por: McElvaney, Oliver J., et al.
Publicado: (2021)

Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients
por: Janciauskiene, Sabina, et al.
Publicado: (2020)

Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden
por: Tanash, Hanan A, et al.
Publicado: (2016)

Acoustic radiation force impulse (ARFI) elastography in a cohort of alpha-1 antitrypsin-deficient individuals and healthy volunteers
por: Diaz, Sandra, et al.
Publicado: (2018)

Liver function in alpha-1-antitrypsin deficient individuals at 37 to 40 years of age
por: Mostafavi, Behrouz, et al.
Publicado: (2017)

Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
por: Hiller, Adriana-Maria, et al.
Publicado: (2019)

Adult and Adolescent Disclosures of Child Sexual Abuse: A Comparative Analysis
por: McGill, Lucy, et al.
Publicado: (2022)

Real-time PCR quantification of plasma DNA in non-small cell lung cancer patients and healthy controls
por: Szpechcinski, A, et al.
Publicado: (2009)

Circulating monocytes from healthy individuals and COPD patients
por: Aldonyte, Ruta, et al.
Publicado: (2003)

Targeting IgG Autoantibodies for Improved Cytotoxicity of Bactericidal Permeability Increasing Protein in Cystic Fibrosis
por: McQuillan, Karen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lvennrk9hv08v32e6hv77gn1fm